| HLX10+HLX208 |
NSCLC With BRAF V600E Mutation
|
I b/Phase Ⅱ
|
A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of HLX208+HLX10 in NSCLC With BRAF V600E Mutation
|
| HLX10+HLX26 |
Solid Tumours
|
Phase I
|
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of HLX26 Monoclonal Antibody Injection in Combination With HLX10 Monoclonal Antibody Injection in Patients With Advanced/Metastatic Solid Tumor
|
| HLX10+HLX07 |
Squamous Non-small-cell Lung Cancer
|
Phase III
|
A Randomized, Open-Label, Multicenter, Phase II Study of HLX07 (Anti-EGFR Antibody) +HLX10 (Anti-PD-1 Antibody) With or Without Chemotherapy Versus HLX10 With Chemotherapy in First Line sqNSCLC
|
| HLX10+Chemo |
Limited-stage Small Cell Lung Cancer
|
Phase III
|
A Randomized, Double-Blind, International Multicenter, Phase III Study to Evaluate the Anti-Tumor Efficacy and Safety of HLX10 or Placebo in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer
|
| HLX04-O |
wet Age-related macular Degeneration
|
Phase III
|
A Phase 3 Randomized Double-masked Active Controlled Study to Compare the Efficacy and Safety of HLX04-O Administered by Intravitreal Injection With Ranibizumab in Subjects With Wet Age Related Macular Degeneration (wAMD)
|
